Pulmonx to Present at the 34th Annual Piper Sandler Healthcare Conference

Pulmonx Corporation (Nasdaq: LUNG) will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York on November 30, 2022, at 11:30 AM PT / 2:30 PM ET.

Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York on November 30, 2022, at 11:30 AM PT / 2:30 PM ET. A live and archived webcast will be available on the company’s investor website.

Pulmonx is known for its minimally invasive treatments for severe lung diseases, including the Zephyr® Endobronchial Valve, which has been used in over 25,000 patients globally. The Zephyr Valve has gained FDA breakthrough device designation and is available in more than 25 countries.

Argus Session date unavailable

-4.71% session move Open Argus

Details

News Market Reaction – LUNG

The recorded move for LUNG in the trading session of this news was -4.71%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York on Wednesday, November 30, 2022, at 11:30 AM PT / 2:30 PM ET.

A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA premarket approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com 

 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What date will Pulmonx participate in the Piper Sandler Healthcare Conference?

Pulmonx will participate in the Piper Sandler Healthcare Conference on November 30, 2022.

What time is Pulmonx's presentation at the Piper Sandler Healthcare Conference?

Pulmonx's presentation is scheduled for 11:30 AM PT / 2:30 PM ET.

How can I watch Pulmonx's presentation at the healthcare conference?

You can watch Pulmonx's presentation live and archived on their investor website.

What are some key products from Pulmonx Corporation?

Pulmonx's key products include the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform.

How many patients have been treated with the Zephyr Valve?

Over 25,000 patients have been treated with the Zephyr Valve.

In how many countries is the Zephyr Valve commercially available?

The Zephyr Valve is commercially available in more than 25 countries.